HIV patients may ditch combo therapy for One-Pill option, study finds
NCT ID NCT00421551
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether HIV patients with long-term viral suppression could switch to a single boosted drug (darunavir/r) instead of staying on a standard combination of drugs. 225 adults with well-controlled HIV took part. The goal was to see if the single-drug approach could keep the virus undetectable for 48 weeks. The results help doctors understand if simpler treatment is safe and effective for some patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Service des maladies infectieuses et tropicales Hopital Pitie salpetriere
Paris, 75013, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop anal lesions from becoming cancer?
- Can resilience defeat HIV stigma? a new study investigates
- Peer support may curb HIV stigma and stress in vietnamese gay men
- A pharmacist's touch: could structured medication reviews boost HIV treatment success?
- A new Fast-Track HIV care model aims to Re-Engage those lost to care
- Can a smartphone app curb HIV risk in south Korea's young gay men?